Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optison for Sentinel Lymph Node Imaging in Breast Cancer
NCT02321527Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2015
- Primary completion
- May 2016
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
Open-label trial of perflutren lipid microspheres in breast cancer, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Number of Breast Cancer Participants With Sentinel Lymph Nodes (SLN) Identification Using the CEUS Technique at 1 day. Started Jul 2015; status: completed.
02
Drugs
perflutren lipid microspheres
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02321527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02321527.